PTO/SB/08s (08-03) Approved for use through 07/31/2008, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

2006-09-15

Iraklievich Gennady Klknadze

o a collection of information unless it contains a valid OMB control number. Application Number

Filing Date

Art Unit

First Named Inventor

Examiner Name

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

				Attorn	ey Doc	ket Number	9771-014US					
					U.S.PATENTS					Remove	1	
Examiner	Cito		Kind		Name of Delegion or Applicant				Pages,Columns,Lines where			
Initial*	No	Patent Number	Code ¹	Issue D	Date	of cited Document			Relevant Passages or Releva Figures Appear			vant
	1	5171623		1992-12	2-15	Yee						
	2	5378524		1995-01	1-03	Blood						
	3	5860626		1999-01	1-19	Moser						
	4	6131853		2000-10	0-17	Bauer et al						
If you wis	h to a	dd additional U.S. Pater	t citatio	n inform	ation pl	ease click the	Add	button.		Add		
			U.S.P.	ATENT	APPLI	CATION PUBL	LICA	TIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹		to Name of Patentee of Applicant				Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1											
If you wish to add additional U.S. Published Application citation information please click the Add button. Add												
				FOREIG	GN PAT	TENT DOCUM	ENT	rs		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Ap	me of Patentee plicant of cited cument	e or V	vhere Re	or Relevan	TS

| Application Number | Filing Date | 2006-09-15 | Filing Date | 2006-09-16 | Filing Date | 2006-09-16

	1	19840303A1	DE		2000-03-09	Dr. Prof. Ingo Brandhorst				
	2	2068502A	GB		1981-08-12	George Applegate		Z		
	3	0679812A1	EP		1995-11-02	Kiknadze, Gennady Iraklievich		Z		
	4	0679812B1	EP		1998-08-19	Vida, Nikolaus		Z		
	5	2004/012987A2	wo		2004-02-12	Board of Regents		Z		
	6	2004/012987A3	wo		2004-02-12	Board of Regents		Z		
If you wis	h to a	dd additional Foreign P				ease click the Add buttor				
			NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove			
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item Initials* No No November (in CAPITAL LETTERS), title of the article (when appropriate), title of the item Initials* No November (in CAPITAL LETTERS), title of the article (when appropriate), title of the item Initials* November (in CAPITAL LETTERS), title of the article (when appropriate), title of the item Initials* November (in CAPITAL LETTERS), title of the article (when appropriate), title of the item Initials* November (in CAPITAL LETTERS), title of the article (when appropriate), title of the item Initials* November (in CAPITAL LETTERS), title of the article (when appropriate), title of the item Initials* November (in CAPITAL LETTERS), title of the article (when appropriate), title of the item Initials* November (in CAPITAL LETTERS), title of the article (when appropriate), title of the item Initials* November (in CAPITAL LETTERS), title of the article (when appropriate), title of the item Initials* November (in CAPITAL LETTERS), title of the article (when appropriate), title of the item Initials* November (in CAPITAL LETTERS), title of the article (when appropriate), title of the item Initials* November (in CAPITAL LETTERS), title of the item Initials* November (in CAPITAL LETTERS), title of the item Initials* November (in CAPITAL LETTERS), title of the item Initials* November (in CAPITAL LETTERS), title of the item Initials* November (in CAPITAL LETTERS), title of the item Initials* November (in CAPITAL LETTERS), title of the item Initials* November (in CAPITAL LETTERS), title of the item Initials* November (in CAPITAL LETTERS), title of the item Initials* November (in CAPITAL LETTERS), title of the item Initials* November (in CAPITAL LETTERS), title of the item Initials* November (in CAPITAL LETTERS), title of the item Initials* November (in CAPITAL LETTERS), title of the item Initials* November (in CAPITAL LETTERS), title of the item Initials* November (in CAPITAL LETTERS), title o									
	1									
If you wish to add additional non-patent literature document citation information please click the Add button Add										
EXAMINER SIGNATURE										
Examiner	Examiner Signature Date Considered									
	*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant									

	Application Number		
INFORMATION DIGGI COURT	Filing Date		2006-09-15
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Iraki		evich Gennady Kiknadze
(Not for submission under 37 CFR 1.99)	Art Unit		
(Examiner Name		
	Attorney Docket Number	r	9771-014US

See for Codes of USPTO Patient Documents at your USPTO, CODE on MEPP 901.04. * Exister office in all research on documents, by the loss before code (WPO) Standard 51.3. * *Projectioned person of the patient obscurred. The patient obscurred is because the search received the patient obscurred. * More of document by the appropriate symbols as indicated on the document with the patient obscurred. * More of document by the appropriate symbols as indicated on the document under WPO Standard 51.56 if possible. * Applicant is to place a check mark here if Exploit language the search can see a support of the patient obscurred.

Application Number Filing Date 2006-09-15 Filing Date 12006-09-15 Filing Date

CERTIFICATION STATEMENT

Please see	37	CFR	1 97	and	1.98	to make	the	appropriate	selection(s):	

information disclosure statement. See 37 CFR 1.97(e)(1).

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(eV).

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Jason Paul DeMont/	Date (YYYY-MM-DD)	2006-09-15
Name/Print	Jason Paul DeMont	Registration Number	35793

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant Affice, U.S. Department of Commence, P. 0. Bot 1450, Alexandria, V.3.251.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.3.231.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicide is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually the principal purpose and for examines your submission, which may visually intermediate or of extended now about the principal purpose.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuint to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs and of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public of the record via yet of sicklosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public of the record via filed in application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.